Disability Benefit Systems
ME/CFS produces profound work disability. Employment rates range from 16.6β27% across studies, with an estimated 75% of patients unable to work (Podell, Dimmock, and Comerford 2020) (see Economic Impact of ME/CFS for the full economic quantification of the employment gap). In the United States, patients face a disability adjudication system designed for conditions with objective biomarkers and predictable functional trajectories β neither of which characterizes ME/CFS.
The U.S. Social Security Administration (SSA) disability determination process relies on objective functional capacity assessments β tests of how much a person can lift, how long they can stand, how far they can walk β to evaluate claims. These assessments systematically underestimate ME/CFS disability because they do not capture post-exertional malaise (PEM), the defining feature of the disease (Podell, Dimmock, and Comerford 2020). A patient who appears functional during a 30-minute physical capacity evaluation may become bedbound 24β48 hours later β a consequence the evaluation neither measures nor predicts. The two-day cardiopulmonary exercise test (2-day CPET), which does capture PEM through repeat exercise testing, is underutilized in disability claims despite providing objective evidence of exertional intolerance. (Certainty: 0.55 β practice guide based on clinical experience with disability adjudication; no systematic study of SSA claim outcomes for ME/CFS specifically.)
Consequence: A disability determination system that measures the wrong thing β single-day functional capacity rather than post-exertional collapse β will systematically deny benefits to patients whose disability is defined by post-exertional collapse. This is not a failure of individual claims adjudicators; it is a structural mismatch between the evaluation method and the disease mechanism. Severity applicability: most critical for severe/very severe patients (β₯50% functional loss), but also relevant for moderate patients who qualify for disability but face assessment methods that do not capture PEM.
No cross-national comparison of disability determination for ME/CFS exists. No study has measured SSA claim approval rates for ME/CFS versus other conditions. No study has evaluated whether 2-day CPET evidence improves claim outcomes. No research exists on employment retention interventions β whether workplace accommodations, flexible scheduling, or remote work programs reduce the rate at which ME/CFS patients exit the workforce. The 75% unable-to-work figure is quoted across multiple sources but has not been independently verified in a large population-representative study.
Consequence: Disability policy for ME/CFS is currently guided by clinical experience and patient advocacy, not by systematic evidence on what works. This is a research gap that has direct financial consequences for patients: every denied claim represents lost income, lost healthcare access, and deepened poverty. Severity applicability: all severity levels, but consequences are most severe for severe/very severe patients who are fully disabled and have no alternative income.